We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Prophylactic Photodynamic Therapy to Organ Transplant Patients

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified May 2008 by Bispebjerg Hospital.
Recruitment status was:  Not yet recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT00365521
First Posted: August 17, 2006
Last Update Posted: June 2, 2008
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Bispebjerg Hospital
August 15, 2006
August 17, 2006
June 2, 2008
April 2009
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00365521 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Prophylactic Photodynamic Therapy to Organ Transplant Patients
Not Provided
To evaluate a possible prophylactic efficacy of photodynamic therapy on the incidence of non-melanoma skin cancer, actinic keratoses, warts and keratoses in recently organ transplanted recipients.
Not Provided
Interventional
Not Provided
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Single
Organ Transplants
Procedure: Photodynamic Therapy
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Unknown status
50
Not Provided
Not Provided

Inclusion Criteria:

  • Organ transplant recipients.
  • Age 40 years or older.

Exclusion Criteria:

  • Patients younger than 40 years and older than 70 years.
  • Clinical signs of skin cancer, actinic keratoses or warts at the time of inclusion.
  • Previous photodynamic therapy to the skin areas investigated.
  • Pregnancy or breast feeding patients.
  • Patients with porphyria.
  • Patients with a tendency to produce hypertrophic scars or keloids.
  • Patients with known allergy to Metvix.
  • Patients who are not considered able to follow the treatment protocol (e.g. severely alcoholic patients, dementia patients, mentally ill patients etc.).
Sexes Eligible for Study: All
40 Years to 70 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Denmark
 
 
NCT00365521
KF-01-314759
Not Provided
Not Provided
Not Provided
Not Provided
Bispebjerg Hospital
Not Provided
Principal Investigator: Merete Hædersdal, MD, PhD, DrMedSci Bispebjerg Hospital
Bispebjerg Hospital
May 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP